Aqilion aims for best-in-class with new programme
Aqilion is in the business of discovering and developing new drug targets that could reduce the burden of chronic inflammatory illnesses. The company has three ongoing pipeline projects, and a fourth programme has just been announced with PKCtheta as the target. Aqilion’s CEO Sarah Fredriksson joined us in the studio to tell us all about it!
See the interview with Aqilion’s CEO Sarah Fredriksson below.
